N-(2-{1-[4-(2-naphthyl)pyrimidin-2-yl]piperidin-4-yl}ethyl)methanesulfonamide | 1123234-70-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(2-{1-[4-(2-naphthyl)pyrimidin-2-yl]piperidin-4-yl}ethyl)methanesulfonamide
• 英文别名: N-[2-[1-(4-naphthalen-2-ylpyrimidin-2-yl)piperidin-4-yl]ethyl]methanesulfonamide
• CAS: 1123234-70-7
• 化学式: C₂₂H₂₆N₄O₂S
• 分子量: 410.54
• InChiKey: JKIUOGOUYBMJIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  83.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
  申请人：Pelletier Jeffrey Claude

  公开号：US20090054392A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.

  本发明涉及萘基嘧啶类似物、制备萘基嘧啶类似物的方法、包含萘基嘧啶类似物的组合物以及治疗与经典Wnt-β-catenin细胞信息传递系统相关的疾病的方法，包括向需要治疗的受试者投予有效量的萘基嘧啶、萘基吡嗪和萘基吡啶类似物。
• SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER
  申请人：CGI Pharmaceuticals, Inc.

  公开号：EP2188267A2

  公开（公告）日：2010-05-26
• [EN] NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM<br/>[FR] ANALOGUES DE NAPHTYLPYRIMIDINE, NAPHTYLPYRAZINE ET NAPHTYLPYRIDAZINE ET LEUR UTILISATION COMME AGONISTES DU SYSTÈME DE COMMUNICATION CELLULAIRE WNT-BÊTA-CATÉNINE
  申请人：WYETH CORP

  公开号：WO2009026319A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-[beta-symbol]-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.
• [EN] NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM<br/>[FR] ANALOGUES DE LA NAPHTHYLPYRIMIDINE, DE LA NAPHTHYLPYRAZINE ET DE LA NAPHTHYLPYRIDAZINE ET LEUR UTILISATION EN TANT QU'AGONISTES DU SYSTÈME DE MESSAGERIE CELLULAIRE WNT-BÊTA-CATÉNINE
  申请人：WYETH CORP

  公开号：WO2009026326A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-[beta-symbol]-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.
• [EN] CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF<br/>[FR] AMIDES SUBSTITUÉS, PROCÉDÉ POUR LES PRÉPARER ET PROCÉDÉ POUR LES UTILISER
  申请人：CGI PHARMACEUTICALS INC

  公开号：WO2009039397A2

  公开（公告）日：2009-03-26

  Compounds of Formula (I) that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula (I), together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.